Language impairment in Alzheimer’s disease and benefits of acetylcholinesterase inhibitors

References

• Alzheimer’s Disease InternationalWorld Alzheimer Report 2010: The global economic impact of dementiaAlzheimer’s Disease International website Available from: http://www.alz.co.uk/research/files/WorldAlzheimerReport.2010.pdfAccessed May 10, 2012
   Google Scholar
• Alzheimer’s Association2012 Alzheimer’s Disease Facts and FiguresAlzheimer’s and Dementia Available from: http://www.alz.org/downloads/Facts_Figures_2012.pdfAccessed May 10, 2012
   Google Scholar
• HebertLEScherrPABieniasJLBennettDAEvansDAAlzheimer disease in the US population: prevalence estimates using the 2000 censusArch Neurol20036081119112212925369
   PubMed Web of Science ®Google Scholar
• FeldmanHHWoodwardMThe staging and assessment of moderate to severe Alzheimer diseaseNeurology200565S10S17
   Web of Science ®Google Scholar
• GelbDJMeasurement of progression in Alzheimer’s disease: a clinician’s perspectiveStat Med20001911–121393140010844704
   PubMed Web of Science ®Google Scholar
• VestalLSmith-OlindeLHicksGHuttonTHartJJrEfficacy of language assessment in Alzheimer’s disease: comparing in-person examination and telemedicineClin Interv Aging20061446747118046923
   PubMed Web of Science ®Google Scholar
• SchwamEXuYCognition and function in Alzheimer’s disease: identifying the transitions from moderate to severe diseaseDement Geriatr Cogn Disord201029430931620395684
   PubMed Web of Science ®Google Scholar
• McKhannGMKnopmanDSChertkowHThe diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s diseaseAlzheimers Dement20117326326921514250
   PubMed Web of Science ®Google Scholar
• MesulamMWicklundAJohnsonNAlzheimer and frontotemporal pathology in subsets of primary progressive aphasiaAnn Neurol200863670971918412267
   PubMed Web of Science ®Google Scholar
• RohrerJDRossorMNWarrenJDAlzheimer’s pathology in primary progressive aphasiaNeurobiol Aging201233474475220580129
   PubMed Web of Science ®Google Scholar
• SavundranayagamMYHummertMLMontgomeryRJInvestigating the effects of communication problems on caregiver burdenJ Gerontol B Psychol Sci Soc Sci2005601S48S5515643047
   PubMed Web of Science ®Google Scholar
• RipichDNFunctional communication with AD patients: a caregiver training programAlzheimer Dis Assoc Disord19948Suppl 3951097999352
   PubMed Web of Science ®Google Scholar
• ManentiRRepettoCBentrovatoSMarconeABatesECappaSFThe effects of ageing and Alzheimer’s disease on semantic and gender primingBrain2004127Pt 102299230615306548
   PubMed Web of Science ®Google Scholar
• Tang-WaiDFGrahamNLAssessment of language function in dementiaGeriatr Aging200811103110
   Google Scholar
• ArrighiHMNeumannPJLieberburgIMTownsendRJLethality of Alzheimer disease and its impact on nursing home placementAlzheimer Dis Assoc Disord2010241909519568155
   PubMed Web of Science ®Google Scholar
• GalaskoDSchmittFThomasRJinSBennettDDetailed assessment of activities of daily living in moderate to severe Alzheimer’s diseaseJ Int Neuropsychol Soc200511444645316209425
   PubMed Web of Science ®Google Scholar
• HilariKNeedleJJHarrisonKLWhat are the important factors in health-related quality of life for people with aphasia? A systematic reviewArch Phys Med Rehabil201293Suppl 1S86S9522119074
   PubMed Web of Science ®Google Scholar
• LamJMWodchisWPThe relationship of 60 disease diagnoses and 15 conditions to preference-based health-related quality of life in Ontario hospital-based long-term care residentsMed Care201048438038720220536
   PubMed Web of Science ®Google Scholar
• BraccoLGallatoRGrigolettoFFactors affecting course and survival in Alzheimer’s disease. A 9-year longitudinal studyArch Neurol19945112121312197986176
   PubMedGoogle Scholar
• CosentinoSScarmeasNAlbertSMSternYVerbal fluency predicts mortality in Alzheimer diseaseCogn Behav Neurol200619312312916957489
   PubMed Web of Science ®Google Scholar
• PotkinsDMyintPBannisterCLanguage impairment in dementia: impact on symptoms and care needs in residential homesInt J Geriatr Psychiatry200318111002100614618551
   PubMed Web of Science ®Google Scholar
• NorthcottSHilariKWhy do people lose their friends after a stroke?Int J Lang Commun Disord201146552453421899670
   PubMed Web of Science ®Google Scholar
• RobertPFerrisSGauthierSIhlRWinbladBTennigkeitFReview of Alzheimer’s disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?Alzheimers Res Ther2010242420796301
   PubMed Web of Science ®Google Scholar
• RosenWGMohsRCDavisKLA new rating scale for Alzheimer’s diseaseAm J Psychiatry198414111135613646496779
   PubMed Web of Science ®Google Scholar
• WinbladBEngedalKSoininenHA 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate ADNeurology200157348949511502918
   PubMed Web of Science ®Google Scholar
• SchmittFACragarDAshfordJWMeasuring cognition in advanced Alzheimer’s disease for clinical trialsJ Neural Transm Suppl20026213514812456059
   PubMedGoogle Scholar
• EmreMMecocciPStenderKPooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer’s diseaseJ Alzheimers Dis200814219319918560130
   PubMed Web of Science ®Google Scholar
• SchmittFAAshfordWErnestoCThe severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer’s disease. The Alzheimer’s Disease Cooperative StudyAlzheimer Dis Assoc Disord199711Suppl 2S51S569236953
   PubMed Web of Science ®Google Scholar
• FerrisSIhlRRobertPSevere Impairment Battery Language scale: a language-assessment tool for Alzheimer’s disease patientsAlzheimers Dement20095537537919751916
   PubMed Web of Science ®Google Scholar
• SchultzRRSivieroMOBertolucciPHFThe cognitive subscale of the “Alzheimer’s Disease Assessment Scale” in a Brazilian sampleBraz J Med Biol Res2001341295130211593304
   PubMed Web of Science ®Google Scholar
• FerrisSHSchmittFASaxtonJAnalyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer’s diseaseAlzheimers Res Ther2011332221689411
   PubMed Web of Science ®Google Scholar
• WinbladBKilanderLErikssonSDonepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled studyLancet200636795161057106516581404
   PubMed Web of Science ®Google Scholar
• BlackSEDoodyRLiHDonepezil preserves cognition and global function in patients with severe Alzheimer diseaseNeurology200769545946917664405
   PubMed Web of Science ®Google Scholar
• CummingsJJonesRWilkinsonDEffect of donepezil on cognition in severe Alzheimer’s disease: a pooled data analysisJ Alzheimers Dis201021384385120634594
   PubMed Web of Science ®Google Scholar
• WinbladBBlackSEHommaADonepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trialsCurr Med Res Opin200925112577258719735164
   PubMed Web of Science ®Google Scholar
• FarlowMRSallowaySTariotPNEffectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind studyClin Ther20103271234125120678673
   PubMed Web of Science ®Google Scholar
• SchmittFAFerrisSHMackellJRichardsonSSunYDonepezil 23 mg/d improves cognitive abilities in patients with moderate to severe Alzheimer’s disease: evaluating the impact on languagePresented at the 63rd Annual Meeting of the American Academy of NeurologyHonolulu, HIApril 9–16, 2011
   Google Scholar
• BurnsABernabeiRBullockRSafety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trialLancet Neurol200981394719042161
   PubMed Web of Science ®Google Scholar
• FarlowMRCummingsJLOlinJTMengXEffects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer’s diseaseAm J Alzheimers Dis Other Demen201025434735220392862
   PubMed Web of Science ®Google Scholar
• GrossbergGTSchmittFAMengXTekinSOlinJReviews: effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer’s diseaseAm J Alzheimers Dis Other Demen201025862763321131668
   PubMed Web of Science ®Google Scholar